Trial Profile
Double-Blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 20 Apr 2012
Price :
$35
*
At a glance
- Drugs Rabeprazole (Primary)
- Indications Reflux oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms TWICE
- Sponsors Eisai Co Ltd
- 20 Mar 2012 Results published in the American Journal of Gastroenterology.
- 10 May 2011 Results presented at the Digestive Disease Week 2011.
- 21 Dec 2010 Twice daily administration of 10mg or 20mg doses approved in Japan based on the results of this trial, according to an Eisai Co media release.